期刊
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1111/jce.15976
关键词
biventricular pacing; cardiac resynchronization therapy; conduction system pacing; His-bundle pacing; left bundle branch pacing
Through analyzing the existing data, it was found that conduction system pacing (CSP) has significant advantages over conventional biventricular pacing (BiVP) in terms of clinical outcomes, including reducing all-cause mortality and heart failure hospitalization. However, further large-scale randomized trials are needed to verify these observations.
IntroductionConduction system pacing (CSP) is observed to produce greater improvements in echocardiographic and hemodynamic parameters as compared to conventional biventricular pacing (BiVP). However, whether these surrogate endpoints directly translate to improvements in hard clinical outcomes such as death and heart failure hospitalization (HFH) with CSP remains uncertain as studies reporting these outcomes are scarce. The aim of this meta-analysis was to analyze the existing data to compare the clinical outcomes of CSP versus BiVP. MethodsA systematic search of the Embase and PubMed database was performed for studies comparing CSP and BiVP for patients indicated to receive a CRT device. The coprimary endpoints were all-cause mortality and HFH. Other secondary outcomes included change in left ventricular ejection fraction (LVEF), change in NYHA class, and increase in NYHA class & GE;1. A random-effects model was chosen a priori to analyze the composite effects given the anticipated heterogeneity of included trials. ResultsTwenty-one studies (4 randomized and 17 observational) were identified reporting either primary outcome and were included in the meta-analysis. In total 1960 patients were assigned to CSP and 2367 to BiVP. Median follow-up time was 10.1 months (ranging 2-33 months). CSP was associated with a significant reduction in all-cause mortality (odds ratio [OR] 0.68, 95% confidence interval [CI]: 0.56-0.83) and HFH (OR 0.52, 95% CI: 0.44-0.63). Mean improvement in LVEF was also greater with CSP (mean difference 4.26, 95% CI: 3.19-5.33). Reduction in NYHA class was significantly greater with CSP (mean difference -0.36, 95% CI: -0.49 to -0.22) and the number of patients with an increase in NYHA class & GE;1 was significantly greater with CSP (OR 2.02, 95% CI: 1.70-2.40). ConclusionsCSP was associated with a significant reduction in all-cause mortality and HFH when compared to conventional BiVP for CRT. Further large-scale randomized trials are needed to verify these observations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据